Beam Therapeutics shares early Phase 1/2 data for BEAM‑301 in glycogen storage disease type Ia
Beam Therapeutics presented initial results from its Phase 1/2 trial of BEAM‑301 in six patients with GSD‑Ia. Two patients receiving the 40 mg dose achieved a 15‑hour fasting period, while the 20 mg group showed a modest increase in fasting time. All participants experienced at least one treatment‑related adverse event, and four had serious events. The company said it will start a 60 mg cohort and will discuss a potential FDA approval pathway.
Why it matters
Beam says the data provide clinical proof of concept for BEAM‑301, which could drive future valuation if the program advances toward approval. The safety profile and upcoming 60 mg cohort will inform dosing and regulatory discussions, affecting investor expectations for the biotech’s pipeline.
Key facts
- 1The trial enrolled six patients who received a single intravenous infusion of BEAM‑301 at either 20 mg or 40 mg. investing.com
- 2Median follow‑up was 7.6 months as of the August 17 2026 data cutoff. investing.com
- 3In the 40 mg group, two patients reached a 15‑hour fasting window, eliminating the need for starch supplementation. investing.com
- 4For the 40 mg cohort, the median time before fasting‑induced hypoglycemia rose from about 2.5 hours at baseline to roughly 15 hours by day 36. investing.com
- 5In the 20 mg cohort, the median fasting time increased from about 2.9 hours at baseline to roughly 4.3 hours. investing.com
- 6All six patients experienced at least one treatment‑emergent adverse event considered related to BEAM‑301; four patients had serious events, including three Grade 3 infusion‑related reactions. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.